CRISPR Therapeutics (NASDAQ:CRSP) executives highlighted progress across its oncology and autoimmune cell therapy pipeline ...
Indian American researcher developing a novel type of living T cell-based therapy to tackle obesity-induced diabetes ...
CRISPR Therapeutics stays a Hold as CASGEVY launch lags; watch cash burn, revenue delays, and CTX310/CTX611 catalysts for 2026. Click here to read now.
Antibiotic resistance is racing toward a global crisis, with “superbugs” projected to cause over 10 million deaths annually ...
CRISPR Therapeutics’ gene-editing treatments are highly customized and shockingly expensive. The market is watching to see if the underlying science can be applied to treat many diseases. The company ...
Researchers at Texas A&M are pairing a widely used ingredient with advanced medical technology to develop new treatments for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results